Cytek Biosciences, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone Q4 filing; it reports Q4 revenue of $48.3 million but does not provide a clear Q4 year-over-year comparison in the supplied text. The company develops and sells full-spectrum flow cytometry instruments, reagents, software and services. Its principal platforms include Aurora, Northern Lights and Aurora CS.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Revenue | $164.0 million | $128.0 million | +28% |
| Product revenue | $148.6 million | $119.5 million | +24% |
| Service revenue | $15.4 million | $8.4 million | +83% |
| Gross profit / gross margin | $101.0 million / 62% | $79.1 million / 62% | Margin unchanged |
| Operating income (loss) | ($1.8 million) | $9.2 million | Declined |
| Net income | $2.5 million | $3.0 million | Declined |
| Operating cash flow | ($12.2 million) | $4.6 million | Turned negative |
- Product gross margin declined to 66% from 69%, primarily due to higher material costs and less favorable instrument mix. Service margin improved to 15% from negative 36%, reflecting a larger installed base and more instruments moving beyond warranty.
- Operating expenses rose 47% to $102.8 million: R&D increased 43% to $34.9 million, sales and marketing 34% to $33.2 million, and G&A 66% to $34.7 million. Management attributed the increases chiefly to hiring, compensation and infrastructure investment.
- At year-end, cash and cash equivalents were $296.6 million, marketable securities $44.5 million, and restricted cash $2.9 million. Current assets were $454.0 million and current liabilities $49.0 million. Cash and cash equivalents were down from $364.6 million at year-end 2021.
- Investing cash outflow was $55.9 million, including $44.5 million of marketable-security purchases and $9.7 million of property and equipment purchases. Financing cash inflow was $5.5 million. The company reported $2.3 million of long-term debt and $17.8 million of BD settlement liability.
Material changes and notable items
- Growth was driven by continued Aurora and Northern Lights sales, increased Aurora CS sales, recently launched reagents and consumables, and higher average blended selling prices attributed to product mix. Instrument shipments reached 1,670 cumulatively by year-end.
- Receivables increased to $48.9 million from $29.8 million, and inventory to $48.2 million from $32.2 million. These working-capital increases contributed to negative operating cash flow.
- Revenue recognized under bill-and-hold arrangements was $12.1 million; $5.9 million of revenue related to products that had not shipped at year-end. Remaining performance obligations totaled $26.1 million, primarily service revenue.
- On February 28, 2023, after year-end, Cytek completed its acquisition of Luminex’s flow cytometry and imaging business for approximately $46.5 million in cash. The acquired business includes Amnis-, CellStream-, Guava- and Muse-branded products. The 2022 financial statements do not include the acquisition’s operating results.
- The company’s 2022 results include $16.6 million in stock-based compensation. Its BD agreement includes continuing low-single-digit royalties on certain product sales for ten years; the $6.0 million sales milestone was paid in 2021.
Outlook, risks and controls
Management expects continued investment in R&D, sales and marketing, international expansion, manufacturing and new products; it expects expenses to rise. It stated that existing cash and anticipated operating cash flows should cover working-capital and capital-expenditure needs for at least 12 months from the filing date. No specific numeric revenue or earnings guidance is provided.
- Key business risks include reliance on a limited range of instrument products, lengthy and variable sales cycles, dependence on single- or limited-source suppliers, inventory and demand forecasting, competition, and reliance on academic and government research funding.
- Most U.S. products are marketed for research use only. Clinical-market expansion depends in part on regulatory approvals; the Northern Lights CLC is approved for clinical use in the EU and China.
- Management identified material weaknesses in internal control over financial reporting, including insufficient qualified accounting and IT resources, ineffective control design and review, IT access and change-management deficiencies, and weaknesses in journal-entry and account-reconciliation controls. Management and the auditor concluded controls were ineffective at December 31, 2022; Deloitte issued an adverse opinion on internal control. Deloitte issued an unqualified opinion on the financial statements.
- Other disclosed uncertainties include inflation and economic weakness, foreign-exchange exposure (the company reported no hedging arrangements), cybersecurity and data privacy, regulatory compliance, intellectual-property disputes, and integration of acquisitions.
Important facts for investors to verify
- Whether revenue growth can translate into sustained operating profitability and positive operating cash flow as spending continues to increase.
- Whether the elevated receivables, inventory and bill-and-hold revenue convert to cash and shipments, and whether inventory write-downs or collection issues emerge.
- Progress, independent auditor assessment and timing of remediation of the material weaknesses in financial reporting controls.
- The acquired business’s contribution, integration costs, transition-supply arrangements and cash requirements following the $46.5 million acquisition.
- Exposure to supplier concentration and the effect of product mix, material costs, royalties and service growth on gross margins.